SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Munch-a-Biotech Today

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong3/21/2019 9:22:58 PM
  Read Replies (1) of 3157
 
In an interview on CNBC, a Jefferies analyst said that Biogen ( BIIB -29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company ( BHVN +8.2%), Neurocrine Biosciences ( NBIX +5.9%), Alder BioPharmaceuticals ( ALDR +6.2%), Sage Therapeutics ( SAGE +3.6%), ACADIA Pharmaceuticals ( ACAD +3.7%) and GW Pharmaceuticals ( GWPH +3.3%).

A Stifel analyst agreed, adding that Sarepta Therapeutics ( SRPT +2.1%) could be a target as well.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext